The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11032 results:
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.. Curr Vasc Pharmacol. 7(3), 264-6.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention.. Circ J. 77(5), 1348.
Athyros, V. G., & Mikhailidis D. P. (2014).  Therapy: Caloric and fat intake in statin users.. Nat Rev Endocrinol. 10(8), 450-1.
Athyros, V. G., Kakafika A., Karagiannis A., & Mikhailidis D. P. (2007).  Statins and regression of coronary atherosclerosis.. JAMA. 297(20), 2197; author reply 2197.
Athyros, V. G., Hatzitolios A., Karagiannis A., Didangelos T. P., Iliadis F., Dolgyras S., et al. (2009).  Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study.. Curr Med Res Opin. 25(8), 1931-40.
Athyros, V. G., & Doumas M. (2018).  Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality.. Curr Vasc Pharmacol. 16(3), 206-208.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Atorvastatin: safety and tolerability.. Expert Opin Drug Saf. 9(4), 667-74.
Athyros, V. G., Pagourelias E. D., Gossios T. D., & Vasilikos V. G. (2015).  Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?. Curr Vasc Pharmacol. 13(3), 368-80.
Athyros, V. G., Ganotakis E. S., Elisaf M. S., Liberopoulos E. N., Goudevenos I. A., & Karagiannis A. (2007).  Prevalence of vascular disease in metabolic syndrome using three proposed definitions.. Int J Cardiol. 117(2), 204-10.
Athyros, V. Gabriel, Doumas M., & Karagiannis A. (2016).  Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action.. Indian Heart J. 68(5), 596-598.
Athyros, V. G., Katsiki N., & Karagiannis A. (2014).  Editorial: (Persistent elevation of blood pressure in children and adolescents is associated with arterial hypertension and premature atherosclerosis in adults. Is it possible to reverse this?).. Curr Vasc Pharmacol. 12(6), 870-2.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. Expert Opin Pharmacother. 16(10), 1449-61.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?. Curr Pharm Des. 16(34), 3939-847.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Stage of chronic kidney disease and severity of coronary heart disease manifestation.. Expert Opin Pharmacother. 13(4), 457-60.
Athyros, V. G., Karagiannis A., Hatzitolios A. I., Paletas K., Savopoulos C., Giannoglou G., et al. (2009).  Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study.. Curr Med Res Opin. 25(4), 971-80.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and non-alcoholic steatohepatitis.. J Hepatol. 64(1), 241-2.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Should raising high-density lipoprotein cholesterol be a matter of debate?. J Cardiovasc Med (Hagerstown). 13(4), 254-9.
Athyros, V. G., Tziomalos K., & Karagiannis A. (2015).  Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.. Expert Rev Cardiovasc Ther. 13(9), 1059-66.
Athyros, V. G., & Mikhailidis D. P. (2012).  Pharmacotherapy: statins and new-onset diabetes mellitus--a matter for debate.. Nat Rev Endocrinol. 8(3), 133-4.
Athyros, V. G., Kakafika A. I., Karagiannis A., Koragiannis A., Mikhailidis D. P., & Mikhalidis D. P. (2008).  Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.. Am J Cardiol. 101(11), 1679-80.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?. Curr Vasc Pharmacol. 14(6), 494-497.
Athyros, V. G., Katsiki N., & Doumas M. (2018).  Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.. Curr Vasc Pharmacol. 16(2), 104-106.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?. Curr Vasc Pharmacol. 14(1), 88-97.
Athyros, V. G., Doumas M., Imprialos K. P., Stavropoulos K., Georgianou E., Katsimardou A., et al. (2018).  Diabetes and lipid metabolism.. Hormones (Athens). 17(1), 61-67.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease.. Expert Opin Ther Targets. 17(7), 861-2.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.